Skip to content
10-K

Annual Report

Bio-Rad Laboratories, Inc. BIO BIO-B

0000012208-25-000007

← back to feed
Filed
Feb 14, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Eps Diluted FY 2024 · Dec 31, 2024 −$25.57
Eps Diluted FY 2024 · Sep 30, 2024 $23.34
Eps Diluted FY 2024 · Jun 30, 2024 −$76.26
Eps Diluted FY 2024 · Mar 31, 2024 $13.45
Eps Diluted FY 2024 · Dec 31, 2023 $12.14
Eps Diluted FY 2024 · Sep 30, 2023 $3.64
Eps Diluted FY 2024 · Jun 30, 2023 −$39.59
Eps Diluted FY 2024 · Mar 31, 2023 $2.32
Eps Basic FY 2024 · Dec 31, 2024 −$25.57
Eps Basic FY 2024 · Sep 30, 2024 $23.37
Eps Basic FY 2024 · Jun 30, 2024 −$76.26
Eps Basic FY 2024 · Mar 31, 2024 $13.46
Eps Basic FY 2024 · Dec 31, 2023 $12.15
Eps Basic FY 2024 · Sep 30, 2023 $3.65
Eps Basic FY 2024 · Jun 30, 2023 −$39.59
Eps Basic FY 2024 · Mar 31, 2023 $2.33
Eps Basic FY 2024 · Dec 31, 2022 −$121.79
Net Income FY 2024 · Dec 31, 2024 −$715.8M
Net Income FY 2024 · Sep 30, 2024 $653.2M
Net Income FY 2024 · Jun 30, 2024 −$2.17B
Net Income FY 2024 · Mar 31, 2024 $383.9M
Net Income FY 2024 · Dec 31, 2023 $349.7M
Net Income FY 2024 · Sep 30, 2023 $106.3M
Net Income FY 2024 · Jun 30, 2023 −$1.16B
Net Income FY 2024 · Mar 31, 2023 $69M
Net Income restated FY 2024 · Dec 31, 2022 −$3.63B
Gross Profit FY 2024 · Dec 31, 2024 $342M
Gross Profit FY 2024 · Sep 30, 2024 $355.9M
Gross Profit FY 2024 · Jun 30, 2024 $355.1M
Gross Profit FY 2024 · Mar 31, 2024 $325.9M
Gross Profit FY 2024 · Dec 31, 2023 $366.3M
Gross Profit FY 2024 · Sep 30, 2023 $335.7M
Gross Profit FY 2024 · Jun 30, 2023 $362.5M
Gross Profit FY 2024 · Mar 31, 2023 $362.4M
Gross Profit restated FY 2024 · Dec 31, 2022 $1.57B
Long Term Debt FY 2024 · Dec 31, 2023 $1.2B
Short Term Investments restated FY 2024 · Dec 31, 2023 $1.2B
Current Liabilities restated FY 2024 · Dec 31, 2023 $522.8M
Total Liabilities restated FY 2024 · Dec 31, 2023 $3.56B
Current Assets restated FY 2024 · Dec 31, 2023 $3.05B
Total Assets restated FY 2024 · Dec 31, 2023 $12.3B
Shares Diluted FY 2024 · Dec 31, 2022 29.79M sh
Stock Repurchased restated FY 2024 · Dec 31, 2022 $215.7M
Capex restated FY 2024 · Dec 31, 2022 $112.8M
Operating Cash Flow restated FY 2024 · Dec 31, 2022 $194.4M
Cash And Equivalents restated FY 2024 · Dec 31, 2022 $434.2M
Sga Expense restated FY 2024 · Dec 31, 2022 $827.8M
Rd Expense restated FY 2024 · Dec 31, 2022 $256.9M
Operating Income restated FY 2024 · Dec 31, 2022 $482.6M
Cost Of Revenue restated FY 2024 · Dec 31, 2022 $1.23B
Revenue FY 2024 · Dec 31, 2022 $2.8B
Stockholders Equity restated FY 2024 · Dec 31, 2021 $13.69B